Journal
CANCERS
Volume 14, Issue 24, Pages -Publisher
MDPI
DOI: 10.3390/cancers14246174
Keywords
HER3; alteration; bladder cancer; breast cancer; colorectal cancer; lung cancer
Categories
Funding
- American Cancer Society
- [RSG-20-071-01-TBG]
Ask authors/readers for more resources
HER3, a member of the HER family, has been found to play a role in tumor growth and progression. Mutations in HER3 occur in various cancers and may lead to resistance to targeted therapies. Several HER3 targeting drugs are currently under development, potentially improving outcomes for cancer patients with HER3 activation or mutations.
In recent years, the third member of the HER family, kinase impaired HER3, has become a target of interest in cancer as there is accumulating evidence that HER3 plays a role in tumor growth and progression. This review focuses on HER3 activation in bladder, breast, colorectal, and lung cancer disease progression. HER3 mutations occur at a rate up to -10% of tumors dependent on the tumor type. With patient tumors routinely sequenced for gene alterations in recent years, we have focused on HER3 mutations in bladder, breast, colon, and lung cancers particularly in response to targeted therapies and the potential to become a resistance mechanism. There are currently several HER3 targeting drugs in the pipeline, possibly improving outcomes for cancer patients with tumors containing HER3 activation and/or alterations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available